In many cases, we exceeded both our internal goals and external expectations ... For the fourth quarter, we reported positive cash flow from operations of $9 million and had minimal cash capital ...

Get the latest on Legend Biotech’s CARVYKTI, breakthrough myeloma therapies, market expansion, and pipeline at Morgan Stanley’s 2025 Healthcare Conference.

"The reason for the corporation's existence is to simultaneously ensure the mobility rights of Gyeonggi residents and ...